{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}],"title":"Pulse rate, To Low"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"0"}]}],"title":"Pulse rate, To Normal or No change"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"1"}]}],"title":"Pulse Rate, To High"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}],"title":"Temperature, To Low"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"13"},{"groupId":"OG002","value":"1"}]}],"title":"Temperature, To Normal or No Change"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"0"}]}],"title":"Temperature, To High"}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"16"},{"groupId":"OG002","value":"1"}],"units":"Participants"}],"description":"Vital signs (pulse rate and temperature) were measured after resting for at least 5 minutes in a supine or semi-recumbent position. The clinical concern ranges were: For pulse rate (low \\<60 beats per minute \\[bpm\\] and high \\>100 bpm); For body temperature (\\<=35 degrees Celsius or \\>=38 degrees Celsius). Participants were counted in the worst case category that their value changed to (low, normal or high), unless there was no change in their category. Participants whose value category was unchanged, or whose value became normal, were recorded in the \"To Normal or No Change\" category. Participants were counted twice if the participant had values that changed \"To Low\" and \"To High\", so the percentages may not add to 100%. Baseline was the most recent, non-missing value prior to or on the first study treatment dose date.","groups":[{"description":"Participants Cutaneous T cell lymphoma (CTCL) were administered once daily oral dose of 60 mg GSK525762.","id":"OG000","title":"Part 2: GSK525762 60 mg QD CTCL"},{"description":"Participants with Myelodysplastic Syndrome (MDS) were administered once daily oral dose of 75 mg GSK525762","id":"OG001","title":"Part 2: GSK525762 75 mg QD MDS"},{"description":"Participants CTCL were administered once daily oral dose of 80 mg GSK525762","id":"OG002","title":"Part 2: GSK525762 80 mg QD CTCL"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All Treated Population.","reportingStatus":"POSTED","timeFrame":"Up to 36.4 weeks","title":"Part 2: Number of Participants With Worst Case Vital Signs Results Relative to Baseline: Pulse Rate and Body Temperature","type":"SECONDARY","unitOfMeasure":"Participants"}